Table 3.
Immunoreactivity for c-Fos (number of labeled cells/mm2), 2 h after the final session in the rIGT
| noMD VEH |
noMD MIF |
MD VEH |
MD MIF |
Condition × treatment |
Condition (noMD vs MD) |
Treatment (VEH vs MIF) |
|
|---|---|---|---|---|---|---|---|
| l-DG | 100 ± 49.9 | 97 ± 20.5 | 141.2 ± 54 | 55.8 ± 16.7 | F(1,21) = 0.8; p = 0.387 | F(1,21) = 0.0; p = 1 | F(1,21) = 0.9; p = 0.354 |
| r-DG | 100 ± 55.3 | 64.3 ± 17 | 32.6 ± 5.3 | 22.7 ± 5.6 | F(1,24) = 0.3; p = 0.594 | F(1,24) = 5.2; p = 0.032 | F(1,24) = 0.9; p = 0.348 |
| l-CA1 | 100 ± 43.6 | 110.5 ± 32.9 | 93 ± 28 | 85 ± 20.9 | F(1,33) = 0.0; p = 0.779 | F(1,33) = 0.2; p = 0.662 | F(1,33) = 0.0; p = 0.969 |
| r-CA1 | 100 ± 27 | 44.9 ± 16 | 30.5 ± 6.6 | 77.5 ± 17.4 | F(1,30) = 7.7; p = 0.009 | F(1,30) = 1.0; p = 0.324 | F(1,30) = 0.0; p = 0.828 |
| l-CA3 | 100 ± 22.4 | 111.9 ± 32.5 | 93.1 ± 18.9 | 285.4 ± 18.7 | F(1,27) = 1.1; p = 0.239 | F(1,27) = 1.2; p = 0.276 | F(1,27) = 1.8; p = 0.184 |
| r-CA3 | 100 ± 29.3 | 42.1 ± 9.7 | 28.9 ± 6.2 | 53.2 ± 12.8 | F(1,30) = 6.1; p = 0.018 | F(1,30) = 3.3; p = 0.079 | F(1,30) = 1.0; p = 0.318 |
| l-DLS | 100 ± 35.6 | 136 ± 51.2 | 131 ± 36.4 | 70 ± 13.4 | F(1,33) = 1.6; p = 0.215 | F(1,33) = 0.2; p = 0.654 | F(1,33) = 0.1; p = 0.737 |
| r-DLS | 100 ± 40.3 | 106.4 ± 16.3 | 117.3 ± 36.1 | 52.4 ± 9.3 | F(1,34) = 1.7; p = 0.193 | F(1,34) = 0.5; p = 0.500 | F(1,34) = 1.2; p = 0.284 |
| l-DMS | 100 ± 21.1 | 61.6 ± 16.6 | 69 ± 11 | 47 ± 9.7 | F(1,29) = 0.3; p = 0.596 | F(1,29) = 2.3; p = 0.142 | F(1,29) = 4.0; p = 0.052 |
| r-DMS | 100 ± 29.9 | 111.4 ± 26 | 236.1 ± 79.3 | 45.2 ± 7.2 | F(1,33) = 4.6; p = 0.040 | F(1,33) = 0.5; p = 0.466 | F(1,33) = 3.6; p = 0.067 |
| l-Insular | 100 ± 17.4 | 75.3 ± 17.6 | 50.9 ± 16 | 54 ± 15.2 | F(1,32) = 0.6; p = 0.434 | F(1,32) = 4.0; p = 0.054 | F(1,32) = 0.4; p = 0.542 |
| r-Insular | 100 ± 17 | 125.4 ± 23.5 | 128.6 ± 30.1 | 51.6 ± 9.3 | F(1,35) = 4.9; p = 0.033 | F(1,35) = 0.9; p = 0.335 | F(1,35) = 1.2; p = 0.272 |
| l-NaC | 100 ± 24.3 | 89 ± 20.9 | 145.2 ± 28 | 86.6 ± 18.2 | F(1,32) = 0.9; p = 0.346 | F(1,32) = 0.7; p = 0.400 | F(1,32) = 1.9; p = 0.172 |
| r-NaC | 100 ± 34.1 | 85.9 ± 23 | 87.1 ± 23.9 | 65.4 ± 14.4 | F(1,31) = 0.3; p = 0.872 | F(1,31) = 0.5; p = 0.484 | F(1,31) = 0.6; p = 0.453 |
| l-NaS | 100 ± 33.5 | 57.9 ± 16.1 | 74.7 ± 19.2 | 50.8 ± 9.5 | F(1,33) = 0.2; p = 0.640 | F(1,33) = 0.7; p = 0.407 | F(1,33) = 2.9; p = 0.097 |
| r-NaS | 100 ± 28.4 | 147 ± 27.1 | 195.1 ± 53.7 | 72.5 ± 17 | F(1,32) = 5.2; p = 0.029 | F(1,32) = 0.0; p = 0.793 | F(1,32) = 1.0; p = 0.323 |
| l-Cg1 | 100 ± 25.1 | 165.9 ± 41 | 52.2 ± 7.6 | 40.9 ± 9.7 | F(1,27) = 2.4; p = 0.133 | F(1,27) = 12; p = 0.002 | F(1,27) = 1.2; p = 0.282 |
| r-Cg1 | 100 ± 25 | 132.8 ± 22.9 | 94.3 ± 20.2 | 88 ± 15.2 | F(1,30) = 0.8; p = 0.352 | F(1,30) = 1.5; p = 0.232 | F(1,30) = 0.4; p = 0.528 |
| l-Prl | 100 ± 29.2 | 92.7 ± 25.6 | 44.6 ± 10.2 | 59.8 ± 8.5 | F(1,27) = 0.3; p = 0.558 | F(1,27) = 5.3; p = 0.029 | F(1,27) = 0.4; p = 0.837 |
| r-Prl | 100 ± 22.6 | 196.3 ± 38.5 | 119.1 ± 35.6 | 114.1 ± 12.8 | F(1,30) = 3.2; p = 0.081 | F(1,30) = 1.2; p = 0.269 | F(1,30) = 2.6; p = 0.114 |
| l-IL | 100 ± 17.6 | 80.2 ± 27.3 | 44.9 ± 10.9 | 78.3 ± 9.8 | F(1,24) = 2.5; p = 0.125 | F(1,24) = 2.9; p = 0.102 | F(1,24) = 0.2; p = 0.688 |
| r-IL | 100 ± 29.8 | 114.4 ± 21.7 | 112.7 ± 39.2 | 107.6 ± 20.6 | F(1,31) = 0.1; p = 0.737 | F(1,31) = 00; p = 0.919 | F(1,31) = 0.0; p = 0.873 |
| l-latOFC | 100 ± 17.2 | 88.9 ± 19.1 | 81 ± 10.4 | 82.2 ± 18 | F(1,31) = 0.1; p = 0.735 | F(1,31) = 0.5; p = 0.484 | F(1,31) = 0.0; p = 0.788 |
| r-latOFC | 100 ± 7 | 88 ± 12.4 | 79.8 ± 12.2 | 92.1 ± 16.7 | F(1,29) = 0.8; p = 0.383 | F(1,29) = 0.3; p = 0.562 | F(1,29) = 0.0; p = 0.991 |
| l-medOFC | 100 ± 24.6 | 87.4 ± 13.6 | 117.1 ± 17.2 | 129.3 ± 29.3 | F(1,30) = 0.3; p = 0.580 | F(1,30) = 1.8; p = 0.192 | F(1,30) = 0.0; p = 0.992 |
| r-medOFC | 100 ± 18.5 | 132.6 ± 25.1 | 77.5 ± 15.1 | 118.8 ± 30.6 | F(1,31) = 0.0; p = 0.853 | F(1,31) = 0.6; p = 0.442 | F(1,31) = 2.5; p = 0,124 |
| l-venOFC | 100 ± 13 | 82.4 ± 15.4 | 85.1 ± 9.4 | 103.7 ± 25.1 | F(1,31) = 1.0; p = 0.322 | F(1,31) = 0.0; p = 0.860 | F(1,31) = 0.0; p = 0,977 |
| r-venOFC | 100 ± 8.5 | 95.6 ± 10.6 | 80.8 ± 7.6 | 96 ± 15.7 | F(1,31) = 0.6; p = 0.432 | F(1,31) = 0.5; p = 0.449 | F(1,31) = 0.2; p = 0,665 |
After completion of the analysis, all data were normalized to the noMD-VEH group. Experimental animals had been subjected to 24-h MD at PND3 or control treatment. Half of the animals were treated with MIF through oral gavage twice daily on PND26–PND28; the other half received VEH. Data represent mean ± SEM; all groups n = 9-12 animals. l, left; r, right; DG, dentate gyrus; CA1, CA1 region of the hippocampus; CA3, CA3 region of the hippocampus; DSL, dorsolateral striatum; DMS, dorsomedial striatum; NaC, nucleus accumbens core; NaS, nucleus accumbens shell; Cg1, cingulate cortex; PrL, prelimbic cortex; IL, infralimbic cortex; INS, insular cortex; medOFC, medial orbital frontal cortex (OFC); latOFC, lateral OFC; venOFC, ventral OFC.